{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:44:33Z","timestamp":1770230673195,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hyponatremia is one of the complicating findings in acute decompensated heart failure. Decrease in cardiac output and systemic blood pressure triggers activation of renin\u2013angiotensin\u2013aldosterone system, antidiuretic hormone, and norepinephrine due to the perceived hypovolemia. Fluid-overloaded heart failure patients are commonly treated with loop diuretics, acutely decompensated heart failure patients tend to be less responsive to conventional oral doses of a loop diuretic, while other different diuretics could work in different part of nephron circulation system. In this study, we aim to further examine the role of tolvaptan, a vasopressin receptor antagonist, in the treatment of hyponatremia secondary to acutely decompensated heart failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 71 patients with hyponatremia secondary to ADHF were included, and all patients were given tolvaptan. 37 patients were administered tolvaptan early (up until 5\u00a0th day of admission). 34 patients received tolvaptan after 5\u00a0th day of admission mean administration as 6.86\u00a0th day, and median administration was 5\u00a0th day. Analysis showed lower length of stay in patients receiving early administration of tolvaptan compared to late administration (8.86\u2009\u00b1\u20095.06 vs 18.5\u2009\u00b1\u20099.05 p0.001, respectively). Patients with early initiation of tolvaptan also achieved a larger net increase in sodium levels at discharge compared to admission (6.46\u2009\u00b1\u20096.69 vs 3.68\u2009\u00b1\u20094.70 p0.048, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Early administration of tolvaptan in treating hyponatremia in acutely decompensated heart failure patients is associated with a lower length of hospitalization and a higher increase in serum sodium of patients in hyponatremic ADHF patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43044-024-00603-1","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:20:16Z","timestamp":1736760016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Importance of early use of tolvaptan in hyponatremic acutely decompensated heart failure patients, a retrospective study"],"prefix":"10.1186","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-6686","authenticated-orcid":false,"given":"Rarsari","family":"Soerarso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-405X","authenticated-orcid":false,"given":"Emir","family":"Yonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silfi Pauline","family":"Sirait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-5554","authenticated-orcid":false,"given":"Dian Yaniarti","family":"Hasanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-8231","authenticated-orcid":false,"given":"Sunu Budhi","family":"Raharjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3998-1590","authenticated-orcid":false,"given":"Bambang Budi","family":"Siswanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-6759","authenticated-orcid":false,"given":"Maarten J.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-686X","authenticated-orcid":false,"given":"Pim","family":"van der Harst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-518X","authenticated-orcid":false,"given":"Marish I. F. J.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"603_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000493242","volume-title":"Disorders of Fluid and Electrolyte Metabolism: Focus on Hyponatremia","author":"CD Davila","year":"2019","unstructured":"Davila CD, Udelson JE (2019) Hypervolemic Hyponatremia in Heart Failure. In: Peri A, Thompson CJ, Verbalis JG (eds) Disorders of Fluid and Electrolyte Metabolism: Focus on Hyponatremia. S. Karger AG, pp 113\u2013129. https:\/\/doi.org\/10.1159\/000493242"},{"issue":"6","key":"603_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218504","volume":"14","author":"JA Miles","year":"2019","unstructured":"Miles JA, Quispe R, Mehlman Y et al (2019) Racial differences and mortality risk in patients with heart failure and hyponatremia. PLoS ONE 14(6):e0218504. https:\/\/doi.org\/10.1371\/journal.pone.0218504","journal-title":"PLoS ONE"},{"issue":"4","key":"603_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamacardio.2019.5108","volume":"5","author":"G Filippatos","year":"2020","unstructured":"Filippatos G, Angermann CE, Cleland JGF et al (2020) Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiol 5(4):401\u2013410. https:\/\/doi.org\/10.1001\/jamacardio.2019.5108","journal-title":"JAMA Cardiol"},{"issue":"1","key":"603_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1161\/HYPERTENSIONAHA.115.05838","volume":"67","author":"H Zheng","year":"2016","unstructured":"Zheng H, Liu X, Sharma NM, Li Y, Pliquett RU, Patel KP (2016) Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure. Hypertension 67(1):197\u2013205. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05838","journal-title":"Hypertension"},{"issue":"3","key":"603_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, Hung R, Lenihan DJ, Testani JM (2020) Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure. JACC Heart Fail 8(3):157\u2013168. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.012","journal-title":"JACC Heart Fail"},{"issue":"3","key":"603_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrcardio.2014.215","volume":"12","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Valente MAE, Damman K, Hillege HL, Navis G, Voors AA (2015) Diuretic response in acute heart failure\u2014pathophysiology, evaluation, and therapy. Nat Rev Cardiol 12(3):184\u2013192. https:\/\/doi.org\/10.1038\/nrcardio.2014.215","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"603_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF et al (2011) Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. N Engl J Med 365(1):32\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1100171","journal-title":"N Engl J Med"},{"issue":"9860","key":"603_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. The Lancet 381(9860):29\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(12)61855-8","journal-title":"The Lancet"},{"issue":"20","key":"603_CR9","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer M, O\u2019Connor C, McMurray JJV et al (2017) Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med 376(20):1956\u20131964. https:\/\/doi.org\/10.1056\/NEJMoa1601895","journal-title":"N Engl J Med"},{"issue":"7","key":"603_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/CIRCULATIONAHA.106.678359","volume":"116","author":"MW Merx","year":"2007","unstructured":"Merx MW, Weber C (2007) Sepsis and the heart. Circulation 116(7):793\u2013802. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.678359","journal-title":"Circulation"},{"issue":"6","key":"603_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/cs0590443","volume":"59","author":"H Ikram","year":"1980","unstructured":"Ikram H, Chan W, Espiner EA, Nicholls MG (1980) Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 59(6):443\u2013449. https:\/\/doi.org\/10.1042\/cs0590443","journal-title":"Clin Sci (Lond)"},{"issue":"20","key":"603_CR12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia. N Engl J Med 355(20):2099\u20132112. https:\/\/doi.org\/10.1056\/NEJMoa065181","journal-title":"N Engl J Med"},{"issue":"11 Suppl 1","key":"603_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","volume":"120","author":"JG Verbalis","year":"2007","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH (2007) Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 120(11 Suppl 1):S1-21. https:\/\/doi.org\/10.1016\/j.amjmed.2007.09.001","journal-title":"Am J Med"},{"issue":"20","key":"603_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099\u20132112. https:\/\/doi.org\/10.1056\/NEJMoa065181","journal-title":"N Engl J Med"},{"issue":"10","key":"603_CR15","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H et al (2019) JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J 83(10):2084\u20132184. https:\/\/doi.org\/10.1253\/circj.CJ-19-0342","journal-title":"Circ J"},{"issue":"6","key":"603_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S et al (2016) Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J Card Fail 22(6):423\u2013432. https:\/\/doi.org\/10.1016\/j.cardfail.2016.02.007","journal-title":"J Card Fail"},{"issue":"2","key":"603_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ahj.2015.05.003","volume":"170","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Dunning AM, Valente MAE et al (2015) Diuretic response in acute heart failure\u2014an analysis from ASCEND-HF. Am Heart J 170(2):313-321.e4. https:\/\/doi.org\/10.1016\/j.ahj.2015.05.003","journal-title":"Am Heart J"},{"issue":"12","key":"603_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319\u20131331. https:\/\/doi.org\/10.1001\/jama.297.12.1319","journal-title":"JAMA"},{"issue":"1","key":"603_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/hp.2012.02.942","volume":"40","author":"JF Dasta","year":"2015","unstructured":"Dasta JF, Chiong JR, Christian R, Lin J (2015) Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract 40(1):7\u201314. https:\/\/doi.org\/10.3810\/hp.2012.02.942","journal-title":"Hosp Pract"},{"issue":"4","key":"603_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/ehf2.12783","volume":"7","author":"TMH Ng","year":"2020","unstructured":"Ng TMH, Grazette LP, Fong MW, Yoon AJ, Lou M, Kuo A, Upadhyay RY, Han EE, Mehra A, Elkayam U (2020) Tolvaptan vs. furosemide\u2010based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA\u2010AHF). ESC Heart Failure 7(4):1927\u20131934. https:\/\/doi.org\/10.1002\/ehf2.12783","journal-title":"ESC Heart Failure"},{"issue":"1","key":"603_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/jpm13010140","volume":"13","author":"V \u015eorodoc","year":"2023","unstructured":"\u015eorodoc V, Asaftei A, Puha G et al (2023) Management of Hyponatremia in Heart Failure: Practical Considerations. J Pers Med 13(1):140. https:\/\/doi.org\/10.3390\/jpm13010140","journal-title":"J Pers Med"},{"issue":"7","key":"603_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens W, Abrahams Z, Francis GS et al (2009) Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. J Am Coll Cardiol 53(7):589\u2013596. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.068","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"603_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/eurjhf\/hfq195","volume":"13","author":"H Uthoff","year":"2011","unstructured":"Uthoff H, Breidthardt T, Klima T et al (2011) Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 13(4):432\u2013439. https:\/\/doi.org\/10.1093\/eurjhf\/hfq195","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"603_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10741-011-9246-2","volume":"17","author":"B Braam","year":"2012","unstructured":"Braam B, Cupples WA, Joles JA, Gaillard C (2012) Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 17(2):161\u2013175. https:\/\/doi.org\/10.1007\/s10741-011-9246-2","journal-title":"Heart Fail Rev"},{"issue":"4","key":"603_CR25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1523-1755.2004.00902.x","volume":"66","author":"H Funayama","year":"2004","unstructured":"Funayama H, Nakamura T, Saito T et al (2004) Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 66(4):1387\u20131392. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00902.x","journal-title":"Kidney Int"},{"issue":"4","key":"603_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG et al (2010) Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. J Am Soc Nephrol 21(4):705\u2013712. https:\/\/doi.org\/10.1681\/ASN.2009080857","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"603_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00535-015-1052-5","volume":"50","author":"I Sakaida","year":"2015","unstructured":"Sakaida I, Nakajima K, Okita K et al (2015) Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol 50(10):1047\u20131053. https:\/\/doi.org\/10.1007\/s00535-015-1052-5","journal-title":"J Gastroenterol"},{"issue":"5","key":"603_CR28","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/ehf2.14494","volume":"10","author":"R Nishikawa","year":"2023","unstructured":"Nishikawa R, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y, Yamamoto E, Ozasa N, Tada T, Sakamoto H, Seko Y, Shiba M, Yoshikawa Y, Yamashita Y, Kitai T, Taniguchi R, Iguchi M, Nagao K, Kawai T, Komasa A, Kawase Y, Morinaga T, Toyofuku M, Furukawa Y, Ando K, Kadota K, Sato Y, Kuwahara K, Kimura T (2023) The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry. ESC Heart Failure 10(5):3141\u20133151. https:\/\/doi.org\/10.1002\/ehf2.14494","journal-title":"ESC Heart Failure"},{"issue":"6","key":"603_CR29","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1002\/ehf2.14530","volume":"10","author":"R Nomura","year":"2023","unstructured":"Nomura R, Morishita T, Sato Y et al (2023) Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure. ESC Heart Fail 10(6):3573\u20133581. https:\/\/doi.org\/10.1002\/ehf2.14530","journal-title":"ESC Heart Fail"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00603-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-024-00603-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00603-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:40:06Z","timestamp":1736804406000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-024-00603-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s43044-024-00603-1","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethical Institutional Review Board of National Cardiovascular Center Harapan Kita, Jakarta, Indonesia, Decision Letter LB.02.01\/VII\/220\/KEP.063\/2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}